Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | SMG1 | Q96Q15 | 4/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17430285 | 0.89 | LRRK2 (0.44) | ABL1PIK3CASMG1LRRK2 | |
| SCHEMBL17430267 | 0.88 | PIK3CA (0.45) | ABL1PIK3CASMG1LRRK2PIK3CD | |
| SCHEMBL17430288 | 0.85 | SMG1 (0.47) | ABL1PIK3CASMG1LRRK2CDK1 | |
| SCHEMBL17430287 | 0.84 | LRRK2 (0.49) | ABL1PIK3CASMG1LRRK2 | |
| SCHEMBL17430325 | 0.83 | SMG1 (0.47) | PIK3CASMG1LRRK2PIK3CDCDK1 | |
| SCHEMBL17430286 | 0.83 | LRRK2 (0.43) | ABL1PIK3CASMG1LRRK2PIK3CD | |
| SCHEMBL17430277 | 0.83 | ABL1 (0.54) | ABL1PIK3CASMG1LRRK2 | |
| SCHEMBL17430273 | 0.81 | LRRK2 (0.58) | PIK3CASMG1LRRK2 | |
| SCHEMBL17430328 | 0.81 | BRAF (0.43) | PIK3CALRRK2 | |
| SCHEMBL17430278 | 0.80 | PIK3CA (0.42) | ABL1PIK3CASMG1LRRK2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440952-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | LRRK2, LRRC47, LIMK2 | ABL1 352/4885PIK3CA 752/4885SMG1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.